Skip to main content
Midas Edge

Nautilus Biotechnology, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

NAUT$2.32-2.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

Nautilus Biotechnology, Inc.Consolidated Statements of Stockholders’ EquityYears Ended December 31, 2025 and 2024

Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total Stockholders’ Equity
(in thousands, except share amounts) · Shares · Amount
Balances at December 31, 2023125,068,601$13$467,834$(255)$(202,239)$265,353
Issuance of common stock upon exercise of vested stock options790,111—620——620
Issuance of common stock under employee stock purchase plan247,464—524——524
Stock-based compensation expense——12,701——12,701
Other comprehensive income———312—312
Net loss————(70,780)(70,780)
Balances at December 31, 2024126,106,176$13$481,679$57$(273,019)$208,730
Issuance of common stock upon exercise of vested stock options112,085—58——58
Issuance of common stock under employee stock purchase plan251,349—156——156
Stock-based compensation expense——6,844——6,844
Other comprehensive income———186—186
Net loss————(59,001)(59,001)
Balances at December 31, 2025126,469,610$13$488,737$243$(332,020)$156,973
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.